Rising Prevalence Of Endocrine Diseases Driving Growth In The Market: The Driving Engine Behind Endocrinology Drugs Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Endocrinology Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size for endocrinology drugs has seen a slight decrease in recent years. Its projected expansion is from "$26.29 billion in 2024 to $26.2 billion in 2025, exhibiting a compound annual growth rate (CAGR) of -0.3%. Factors contributing to growth during the historic period include a rising global incidence of diabetes, greater government initiatives, increases in healthcare spending, a surge in instances of adrenal gland disorders, heightened demand for insulin analogs, and an increase in the number of endocrinologists.

How Will the Endocrinology Drugs Market Size Evolve and Grow by 2029?
In the coming years, a slight increase is anticipated in the endocrinology drugs market, which is projected to reach $26.37 billion by 2029 with a compound annual growth rate (CAGR) of 0.2%. This prospective growth during the forecast period can be associated with the increasing number of diabetics, heightened incidence of endocrine-related conditions, the surge of hormonal imbalances among teens, and escalating obesity rates. Future market trends will likely encompass technological developments, the uptake of high-tech drug delivery systems, the incorporation of digital health solutions, precision medicine as well as combination therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/endocrinology-drugs-global-market-report

What Drivers Are Propelling the Growth of Endocrinology Drugs Market Forward?
The escalating incidence of endocrine disorders is anticipated to fuel the progression of the endocrinology drugs market. Endocrine disorders are conditions that disrupt the endocrine system, leading to hormonal imbalances or dysregulation that hinder regular bodily operations. Various factors, such as lifestyle modifications, an aging demographic, and enhanced diagnostic methods, have collectively increased the acknowledgment and occurrence of these disorders. Endocrinology medications aid in the management of endocrine disorders by controlling hormone levels, treating glandular malfunctions, and reinstating hormonal equilibrium to relieve symptoms and enhance overall health outcomes. As an example, the National Library of Medicine, a US medical library, reported in May 2023 that around 13 million individuals in the US, equivalent to 4.78% of the nation's population, are suffering from undiagnosed endocrine disorders. Thyroid disease, one of the most common endocrine conditions, represents about 30% to 40% of the patient load in endocrinology practices. Consequently, the increasing prevalence of endocrine disorders is a significant driver for the growth of the endocrinology drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20769&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Endocrinology Drugs Market?
Leading firms in the endocrinology drugs market are concentrating on introducing novel products such as ready-to-use vials to enhance the process of administering medication. These vials come pre-filled and pre-dosed, eliminating the need for any reconstitution or preparation before being administered. For example, in December 2022, Hikma Pharmaceuticals plc, a pharmaceutical company based in the UK, introduced a Levothyroxine sodium injection, prepared in ready-to-use vials at a concentration of 100 mcg/mL. The product is designed for immediate usage, removing reconstitution requirements and cutting down on the possibility of preparation mistakes, thereby boosting patient safety levels. It offers accurate and consistent dosing, crucial for the management of conditions such as hypothyroidism and myxedema coma. Moreover, these ready-to-use vials enhance efficiency for healthcare providers by saving time and guaranteeing accurate administration in emergency care contexts.

What Are the Key Segments in the Endocrinology Drugs Market?
The endocrinology drugs market covered in this report is segmented -

1) By Indication: Hyperthyroidism, Hypothyroidism, Diabetes, Polycystic Ovarian Syndrome, Growth Hormone Disorders, Pituitary Gland Disorders, Other Indications
2) By Therapy Area: Diabetes Drugs, Thyroid Hormone Disorder Drugs, Human Growth Hormone, Testosterone Replacement Therapy, Others Therapy Areas
3) By Distribution Channel: Hospital pharmacies, Online Pharmacies, Retail pharmacies
4) By End User: Hospitals, Ambulatory Surgical Centers, Others End Users

Subsegments:
1) By Hyperthyroidism: Antithyroid Medications, Radioactive Iodine Therapy, Beta Blockers
2) By Hypothyroidism: Levothyroxine-based Medications, Liothyronine-based Medications, Combination Hormonal Therapies
3) By Diabetes: Insulin Therapies, Oral Antidiabetic Drugs (OADs), GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors
4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives, Metformin, Clomiphene Citrate, Anti-Androgens
5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH), Growth Hormone Secretagogues, Growth Hormone Receptor Antagonists
6) By Pituitary Gland Disorders: Somatostatin Analogs, Gonadotropins, Dopamine Agonists
7) By Other Indications: Adrenal Gland Disorders, Osteoporosis, Parathyroid Disorders, Male Hormonal Imbalances

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20769&type=smp

Who Are the Key Players Shaping the Endocrinology Drugs Market's Competitive Landscape?
Major companies operating in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited

What Geographic Markets Are Powering Growth in the Endocrinology Drugs Market?
North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrinology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20769

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.